In 2017, Novo Nordisk’s semaglutide (Ozempic® Novo Nordisk, Copenhagen, Denmark), a long-acting GLP-1 receptor agonist, was approved by the U.S. FDA for type II diabetes, marking a breakthrough in GLP-1 therapeutics [7]. Here, GLP1R is linked to type 2 diabetes mellitus.